Executives at Eli Lilly say they will give 400,000 tablets of their COVID-19 treatment to the Indian government.

The drug, baricitinib, will be used in combination with Gilead Science’s drug remdesivir.

In India, the drug will be used in hospitalized COVID-19 patients who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.

The pandemic is causing morgues and hospitals to overflow in India.